Skip to main content

Table 2 Association of EGFR expression with clinicopathologic parameters in prostatic acinar adenocarcinoma

From: Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma

   n(%) P-Value
   Positive (n = 23) Negative (n = 100)
Age Groups ≤70 years 14(60.9) 63(63) 0.849
> 70 years 9(39.1) 37(37)
Total gleason score 6 1(4.3) 38(38) < 0.001
7 3(13) 26(26)
8 5(21.7) 22(22)
9 14(60.9) 14(14)
WHO grade groupª Grade 1 1(4.3) 38(38) < 0.001
Grade 2 2(8.7) 23(23)
Grade 3 1(4.3) 3(3)
Grade 4 5(21.7) 22(22)
Grade 5 14(60.9) 14(14)
Tumor Quantificationª < 10% 1(4.3) 22(22) 0.007
10–50% 3(13) 32(32)
> 50% 19(82.6) 46(46)
Perineural invasion Present 16(69.6) 30(30) < 0.001
Absent 7(30.4) 70(70)
Lymphovascular invasionª Present 0(0) 3(3) 1.000
Absent 23(100) 97(97)
Extraprostatic extensionª Present 0(0) 7(7) 0.346
Absent 23(100) 93(93)
Seminal vesicle invasion ª Present 2(8.7) 2(2) 0.158
Absent 21(91.3) 98(98)
Recurrence Yes 19(82.6) 14(14) < 0.001
No 4(17.4) 86(86)
  1. Chi square test was applied
  2. ªFisher exact test applied
  3. P-Value≤0.05, considered as significant